Related Experiment Video
Updated: Aug 11, 2026

A Murine Model of Myocardial Ischemia-reperfusion Injury through Ligation of the Left Anterior Descending Artery
Published on: April 10, 2014
Increased plasma thioredoxin in patients with acute myocardial infarction
Hirofumi Soejima1, Hisakazu Suefuji, Shinzo Miyamoto
1Department of Cardiovascular Medicine, Kumamoto University School of Medicine, Honjo, Kumamoto, Japan. yuuki@gpo.kumamoto-u.ac.jp
Insights
Plasma thioredoxin levels are elevated in patients with acute myocardial infarction (AMI). Higher levels indicate a risk for failed coronary reperfusion therapy in AMI patients.
Area of Science:
- Biochemistry
- Cardiology
- Biomarkers
Background:
- Thioredoxin is a key biomarker for oxidative stress.
- Elevated thioredoxin levels are implicated in various cardiovascular conditions.
Purpose of the Study:
- To investigate elevated thioredoxin levels in acute myocardial infarction (AMI) patients.
- To assess the association between thioredoxin levels and coronary reperfusion outcomes.
Main Methods:
- Plasma thioredoxin levels were measured in 51 AMI patients, 30 stable exertional angina (SEA) patients, and 30 chest pain syndrome (CPS) patients.
- Sampling occurred at multiple time points for AMI patients and upon admission for SEA and CPS patients.
Main Results:
- AMI patients exhibited higher admission plasma thioredoxin levels compared to SEA and CPS groups.
- Thioredoxin levels decreased within 12 hours in AMI patients but remained elevated compared to SEA.
- Higher admission thioredoxin levels independently predicted failed emergent reperfusion therapy in AMI.
Conclusions:
- Plasma thioredoxin is elevated in AMI patients.
- Elevated thioredoxin levels may serve as a predictive marker for failed coronary reperfusion in AMI.
Background And Hypothesis:
Thioredoxin is an important biomarker for oxidative stress. We investigated whether thioredoxin levels were elevated in patients with acute myocardial infarction (AMI) and were associated with the results of coronary reperfusion.
Methods:
The present study determined plasma thioredoxin levels in 51 patients with AMI, 30 patients with stable exertional angina (SEA), and 30 patients with chest pain syndrome (CPS). Plasma sampling was performed on admission, at 12 h, 1 week, 2 weeks, and 4 weeks in patients with AMI, and after admission in patients with SEA and CPS.
Results:
Plasma thioredoxin levels on admission were higher in patients with AMI than in those with SEA and CPS. Plasma thioredoxin levels in patients with AMI were decreased in 12 h without further change thereafter. However, thioredoxin levels in patients with AMI remained higher than in those with SEA. In multivariate analysis, higher levels of thioredoxin on admission were a risk factor for failure in emergent reperfusion therapy in patients with AMI independent of other factors.
Conclusion:
Plasma thioredoxin levels are elevated in patients with AMI, and higher thioredoxin levels may predict subsequent failed coronary reperfusion therapy in patients with AMI.
Related Concept Videos
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Acute Coronary Syndrome III: Diagnostic Studies

